01 · The Perspective
The strip in the kitchen cupboard
The story below is illustrative. It is not about a real person.
A man buys his father's blood pressure medicine from the same pharmacy every month. One month, the strip looks slightly different. He scans the QR code, and a page loads with technical details he cannot interpret.
Two months later, a newspaper reports that a batch of that medicine failed quality tests. He has no way to know whether his father's strips were from that batch. The pharmacist does not know either.
02 · The Perspective
Thousands of failed samples a year
According to a written reply by the Union Health Minister to the Lok Sabha, reported by PTI in December 2025, about 1.16 lakh drug samples were tested in 2024-25. 3,104 were declared not of standard quality and 245 spurious or adulterated. In 2023-24, of about 1.06 lakh samples, 2,988 were not of standard quality and 282 spurious or adulterated.
Most medicines in India are safe. The problem is that patients cannot tell which ones are not.
03 · The Perspective
More is in place than most patients know
- Monthly drug alerts. CDSCO and state regulators publish lists of drug samples that fail tests.
- QR codes. Required on many active pharmaceutical ingredients and on top-selling drug brands.
- Risk-based inspections of manufacturing sites by central and state regulators.
- Pharmacovigilance. The Pharmacovigilance Programme of India collects reports of adverse drug reactions.
04 · The Perspective
Where trust breaks
- Alerts do not reach patients. They are published as technical lists.
- QR results are unreadable. A code that shows data, but not "safe" or "not safe", does not build trust.
- Recalls stop at the warehouse. Patients who have already bought a failed batch are not told.
- Pharmacies cannot trace batches to the patients they sold them to.
- Lab confirmation is slow, so suspect medicines stay on shelves.
05 · The BIBD proposal
The redesign: a Medicine Trust OS
A design to test. Not a claim of achieved outcomes.
A clear verify-before-you-buy check.
Scan or type a code and get a simple answer: genuine, recalled or unknown.
Plain-language QR results, in Indian languages, with what to do next.
Recall alerts that reach the patient, through pharmacies, e-pharmacies and prescription records.
Pharmacy-level traceability.
Batches recorded at sale, so recalls can be targeted.
Fast lab confirmation when a pharmacist or patient reports a suspect product.
06 · Design + AI
Where AI helps, and where regulators decide
AI can flag suspicious patterns in drug alerts, complaints and sales data, and help target inspections.
Regulators and accredited labs make the final call on quality. Patients should always check with a pharmacist or doctor before stopping a medicine.
07 · A testable next step
Start with one state
One state drug controller can pilot plain-language QR checks, batch tracking at pharmacies and patient recall alerts for high-use medicines for a year. Our planning estimate is ₹1 to 1.5 crore.
The measures that matter are patients reached by recall alerts, time from failed test to removal from shelves, and verification checks used by buyers.
08 · Who must act
What each of us can do
| Patients | buy from licensed pharmacies, keep your bill and ask your pharmacist about any medicine that looks different. |
|---|---|
| Pharmacies and e-pharmacies | record batch numbers at sale. |
| CDSCO and state drug controllers | publish alerts in plain language and push them to pharmacies. |
| Manufacturers | make QR results simple and meaningful. |
| Testing labs | offer fast checks on suspect samples. |
09 · The Perspective
Trust that can be verified
Patients should not have to become medicine detectives. When every strip can be checked in seconds, and every recall reaches the person who bought it, trust becomes something the system earns.